CF
MRNA icon

Concorde Financial’s Moderna MRNA Stock Holding History

Concorde Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,648
Closed -$1.18M – 37
2024
Q3 		$1.18M Buy
17,648
+448
+3% +$41.1K 0.69% 33
2024
Q2 		$2.04M Buy
17,200
+127
+0.7% +$16.1K 1.34% 29
2024
Q1 		$1.82M Sell
17,073
-3,062
-15% -$309K 1.65% 17
2023
Q4 		$2M Buy
+20,135
New +$1.69M 1.37% 30
2023
Q3 		– Sell
-21,273
Closed -$2.58M – 33
2023
Q2 		$2.58M Sell
21,273
-270
-1% -$36K 1.69% 30
2023
Q1 		$3.31M Sell
21,543
-717
-3% -$118K 2.41% 20
2022
Q4 		$2.63M Hold
22,260
– – 1.78% 25
2022
Q3 		$2.63M Buy
22,260
+5,809
+35% +$881K 1.78% 25
2022
Q2 		$2.35M Sell
16,451
-675
-4% -$96.5K 2.62% 18
2022
Q1 		$2.4M Buy
17,126
+2,378
+16% +$400K 1.47% 31
2021
Q4 		$3.49M Buy
+14,748
New +$4.31M 2.19% 22

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Concorde Financial's MRNA Position: Q4 2024 in Review

Concorde Financial sold out of Moderna (MRNA) in Q4 2024, closing a stake of 17,648 shares — an estimated $1.18M sold.

Concorde Financial first reported a position in MRNA in Q4 2021 and held it in 11 quarters. The position peaked at $3.49M in Q4 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Concorde Financial reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Concorde Financial sold 17,648 Moderna shares in Q4 2024, an estimated $1.18M.
  • Concorde Financial first reported a position in Moderna in Q4 2021 and held it in 11 quarters.
  • Concorde Financial's Moderna position peaked at $3.49M in Q4 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Concorde Financial's 13F filing for Q4 2024, filed 14 Feb 2025.